8-K current report · filed Jul 14, 2026

CAPRICOR THERAPEUTICS, INC. (CAPR) 8-K Current Report: July 14, 2026

Item 2.03Item 1.01CAPR overview

Short answer

CAPRICOR THERAPEUTICS, INC. (CAPR) filed an 8-K current report with the SEC on July 14, 2026 reporting Item 2.03 (Creation of a Direct Financial Obligation), Item 1.01 (Entry into a Material Definitive Agreement). New 171,000-square-foot San Diego headquarters, adding manufacturing cleanrooms and R&D capacity.

CAPRICOR THERAPEUTICS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • New 171,000-square-foot San Diego headquarters, adding manufacturing cleanrooms and R&D capacity
  • Initial base rent approximately $958,000 monthly, with annual 3.0% increases and operating costs borne by Capricor
  • 18-month full rent abatement plus six-month partial abatement, materially delaying cash rent obligations
  • Lease commencement tied to Deramiocel FDA approval or December 31, 2026, with termination rights if approval is not received
  • Approximately $958,000 security deposit, signaling a significant long-term facility commitment contingent on regulatory progress

Item 2.03 · Creation of a Direct Financial Obligation

  • Item 2.03 incorporates Item 1.01, indicating any financial obligation stems from the material agreement described there
  • Investors must review Item 1.01 for the underlying agreement and potential cash commitments

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other CAPRICOR THERAPEUTICS, INC. 8-K filings

Get the next CAPR 8-K as it lands

Follow CAPR for push alerts, or ask the research agent what this filing means.